噬菌体及其治疗细菌感染的研究进展

doi:10.11843/j.issn.1671-7236.2015.03.041

摘要/Abstract

摘要： 噬菌体在其发现之初便被用于细菌感染的治疗.然而,随着抗生素时代的到来,噬菌体的研究便被忽略.近半个世纪以来,耐药菌株不断出现,抗生素治疗面临巨大挑战.噬菌体作为细菌的天然杀手,对细菌性疾病有很好的治疗效果,其研究价值逐渐引起科学家们的重视.作者对噬菌体、噬菌体治疗细菌感染的应用、噬菌体制剂、噬菌体治疗局限性及发展趋势等方面作一简要概述.

关键词: 噬菌体; 细菌感染; 噬菌体治疗; 噬菌体制剂; 裂解酶

Abstract: At the time of bacteriophage's discovery,bacteriophage therapy was regarded as a possible treatment method against bacterial infection.However,it was abandoned with the arrival of the antibiotic era.Nearly half a century,the ongoing evolution of bacterial multidrug-resistance had recently motivated the scientists to reevaluate bacteriophage therapy for bacterial infections.This paper summarized bacteriophage,the application of bacteriophage therapy of bacterial infection,bacteriophage preparation,the deficiency of bacteriophage therapy and development trend and prospects of bacteriophage therapy.

Key words: bacteriophage; bacterial infection; bacteriophage therapy; bacteriophage preparation; lytic enzymes

中图分类号:

R515

朱育玮, 李玉保, 王守荣, 吴伟胜, 夏光州, 肖传刚. 噬菌体及其治疗细菌感染的研究进展[J]. 《中国畜牧兽医》---唯一指定的官方网站, 2015, 42(3): 769-773.

ZHU Yu-wei, LI Yu-bao, WANG Shou-rong, WU Wei-sheng, XIA Guang-zhou, XIAO Chuan-gang. Research Progress on Bacteriophage and the Therapy in Bacterial Infection[J]. , 2015, 42(3): 769-773.

参考文献

[1] Twort F W.An investigation on the nature of ultra-microscopic viruses[J].Lancet,1915,186(4):1241-1243.

[2] d'Herelle F.On an invisible microbe antagonistic to dysentery bacilli[J].Comptes Rendus Acad Des Sci,1917,165(3):373-375.

[3] Maura D,Debarbieux L.Bacteriophages as twenty-first century antibacterial tools for food and medicine[J].Appl Microbiol Biotechnol,2011,90(3):851-859.

[4] Brussow H,Kutter E.Bacteriophages:Biology and applications[M].Florid:CRC Press,2005.

[5] Ackermann H W.Frequency of morphological phage descriptions in the year 2000[J].Archives of Virology,2001,146:843-857.

[6] Lenski R E.Dynamics of interactions between bacteria and virulent bacteriophage[J].Adv Microb Ecol,1988,10:1-44.

[7] Chatterjee S,Rothenberg E.Interaction of bacteriophage Ⅰ with itsE.coli receptor,Lam B[J].Viruses,2012,4(11):3162-3178.

[8] 李灏.畜禽肠道致病菌及其噬菌体的分离及特性研究[D].济南:山东大学,2002.

[9] 司樨东.噬菌体学[M].北京:科学出版社,1996.

[10] Phillippa C,Ian C.Natural Campylobacter control with bacteriophage[J].World Poultry,2006,26(6):25-26.

[11] Smith H W,Huggins M B.Experimental infection of calves,piglets and lambs with mixtures of invasive and enteropathogenic strains of Escherichia coli[J].Med Microbiol,1979,12(4):507-510.

[12] Smith H W,Huggins M B.Successful treatment of experimentalEscherichia coli infections in mice using phage:Its general superiority over antibiotics[J].Gen Microbiol,1982,128(2):307-318.

[13] Smith H W,Huggins M B.Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves,piglets and lambs[J].Gen Microbiol,1983,129(8):2659-2675.

[14] Abedon S T,Kuhl S J,Blasdel B G,et al.Phage treatment of human infections[J].Bacteriophage,2011,1(2):66-85.

[15] Tanji Y,Shimada T,Fukudomi H,et al.Therapeutic use of phage cocktail for controlling Escherichia coli O157∶H7 in gastrointestinal tract of mice[J].Biosci Bioeng,2005,100(3):280-287.

[16] Tanji Y,Shimada T,Yoichi M,et al.Toward rational control of Escherichia coli O157∶H7 by a phage cocktail[J].Appl Microbiol Biotechnol,2004,64(2):270-274.

[17] Sheng H,Knecht H J,Kudva I T,et al.Application of bacteriophages to control intestinal Escherichia coli O157∶H7 levels in ruminants[J].Appl Environ Microbiol,2006,72(8):5359-5366.

[18] Atterbury R J,Van Bergen M A P,Ortiz F,et al.Bacteriophage therapy to reduce salmonella colonization of broiler chickens[J].Appl Environ Microbiol,2007,73(14):4543-4549.

[19] Capparelli R,Parlato M,Borriello G,et al.Experimental phage therapy against Staphylococcus aureus in mice[J].Antimicrob Agents Chemother,2007,51(8):2765-2773.

[20] Morello E,Saussereau E,Maura D,et al.Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains:First steps towards treatment and prevention[J].PLoS One,2011,6(2):e16963.

[21] Karumidze N,Kusradze I,Rigvava S,et al.Isolation and characterization of lytic bacteriophages of Klebsiella oxytoca[J].Curr Microbiol,2013,66(3):251-258.

[22] Birendra R,Tiwari K,Shukho K,et al.Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models[J].Microbiology,2011,49(6):994-999.

[23] Tang F,Li Y Z,Zhang W,et al.Complete genome sequence of T4-like Escherichia coli bacteriophage HX01[J].J Virol,2012,86(24):13871.

[24] Golshahi L,Lynch K H,Dennis J J,et al.In vitro delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis[J].J Appl Microbiol,2011,110(1):106-117.

[25] Fu W,Forster T,Mayr O,et al.Bacteriophage cocktail for the prevention of biofilm formation by Pseudomanas aeruginosa on catheters in an in vitro model system[J].Antimicrob Agents Chemother,2010,54(1):397-404.

[26] Bokyung S,Jiae Y,Jeong L,et al.Characterization of LysB4,an endolysin from the Bacillus cereus-infecting bacteriophage B4[J].BMC Microbiology,2012,12(15):33.

[27] Nariya H,Miyata S,Tamai E,et al.Identification and characterization of a putative endolysin encoded by episomal phage phiSM101 ofClostridium perfringens[J].Appl Microbiol Biotechnol,2011,90(6):1973-1979.

[28] Burrowes B,Harper D R,Anderson J,et al.Bacteriophage therapy:Potential usesin the control of antibiotic-resistant pathogens[J].Expert Rev Anti Infec Ther,2011,9(9):775-785.

[29] Harper D R,Morales S.Bacteriophage therapy:Practicability and clinical need meet in the multidrug-resistance era[J].Future Microbiol,2012,7(7):797-799.

[30] Loc-Carrillo C,Abedon S T.Pros and cons of phage therapy[J].Bacteriophage,2011,1(2):111-114.

[31] Carlton R M,Noordman W H,Biswas B,et al.Bacteriophage P100 for control of Listeria monocytogenes in foods:Genome sequence,bioinformatic analyses,oral toxicity study,and application[J].Regul Toxicol Pharmacol,2005,43(3):301-312.

[32] Fischetti V A.Novel method to control pathogenic bacteria on human mucous membranes[J].Ann NY Acad Sci,2003,987:207-214.

[33] Borysowski J,Weber-Dabrowska B,Gorski A.Bacteriophage endolysins as a novel class of antibacterial agents[J].Exp Biol Med (Maywood),2006,231(4):366-377.

[34] Eyer L,Pantucek R,Zdrahal Z,et al.Structural protein analysis of the polyvalent Staphylococcal bacteriophage 812[J].Proteomics,2006,7(1):64-72.

[35] Croft A C,D'Antoni A V,Terzulli S L.Update on the anti-bacterial resistance crisis[J].Med Sci Monit,2007,13(6):103-118.

[36] Grisaru-Soen G,Sweed Y,Lerner-Geva L,et al.Nosocomial bloodstream infections in a pediatric intensive careunit:3-year survey[J].Med Sci Monit,2007,13(6):251-257.

[37] Zhou Z,Guan R,Yang Y,et al.Identification of New Delhi metallo-β-lactamase gene (NDM-1) from a clinical isolate ofAcinetobacter junii in China[J].Can J Microbiol,2012,58(1):112-115.

[38] Pouillot F,Chomton M,Blois H,et al.Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b∶H4-ST131 Escherichia coli strain producing CTX-M-15[J].Antimicrob Agents Chemother,2012,56(7):3568-3575.

[39] Birendra R,Tiwari K,Shukho K,et al.Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models[J].Microbiology,2011,49(6):994-999.

编辑推荐 0

Metrics

阅读次数

全文

160

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	160

来源	本网站	其他网站

次数	22	138
比例	14%	86%

摘要

400

最新录用	在线预览	正式出版

0	0	400

来源	本网站	其他网站

次数	195	205
比例	49%	51%